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Breast cancer in men is uncommon, and even more rare is the simultaneous presentation of two diﬀerent malignancies. A 39-year-
old man was diagnosed with both breast cancer and axillary lymphoma. Familiar history revealed that his mother died because
of breast cancer. The patient underwent ﬁne needle aspiration leading to the diagnosis of malignant lesion. Modiﬁed radical
mastectomy was performed. Histology revealed an inﬁltrating ductal carcinoma 2.8cm wide, grade 2, with vascular and lymphatic
invasion. Surprisingly, one of the second level nodes was conﬁrmed as a high-grade large B cell non-Hodgkin’s lymphoma. No
family inheritance or gene mutations (BRCA 1 and 2) were found. The patient underwent local radiotherapy, followed by 6
chemotherapy courses (RCHOP) and treatment with tamoxifen 20mg/daily. To our knowledge, this is the ﬁrst case reported
in literature of male breast cancer and axillary lymphoma simultaneously conﬁrmed in the same patient.
1.Introduction
Male breast carcinoma (MBC) is very uncommon, account-
ingallovertheworldforalmost1%ofallbreastmalignancies
[1]. The annual incidence of male breast cancer in Europe
has been estimated not to exceed 1 out 100,000 [2–4], and
in the U.S. 1,690 new cases were diagnosed in the year
2005 with a 25% mortality rate [5]. This high mortality rate
may be due to a delay between the onset of symptoms and
diagnosis because of a limited awareness of breast cancer risk
in males compared to women. While the incidence of female
breast cancer is rising up, the incidence of male breast cancer
remains almost stable throughout the world [6–8]. In male
patients, the risk of developing breast cancer increases with
age, and the highest incidence is observed between 5 and
10 years later if compared to women [9, 10]. The annual
incidence increases steadily from 35 years of age from 0.1
per 100,000 up to 11.1 per 100,000 in people aged ≥85
years [9]. Optimal management of male breast cancer is not
clearly established, and treatment guidelines have not been
pr ovided,ma ybebecausemostofthea vailableliteratur ec on-
sists of individual case reports. An international multicentric
study of ﬁrst and second primary neoplasms associated with
male breast cancer, carried out on 3,409 patients by pooling
data from 13 cancer registries, has found an increase of male
breast cancers following lymphohematopoietic neoplasms
[10]. Risk factors mainly involve abnormalities in oestrogen
and androgen balance (i.e. patients with gynaecomastia,
undescended testes, Klinefelter’s syndrome, and people who
underwent orchidectomy [11–24]. The authors describe here
the ﬁrst synchronous case reported in literature of male
breastcarcinomainayoungpatient,whowassimultaneously
aﬀected by an axillary lymphoma. Actually, the existing
reports describe few similar cases only in women [25]. Cur-
rently, no relationship between the two diseases is known.
2.CaseReport
A 39-year-old man with no signiﬁcant medical history was
examined as outpatient at the oncology department of
Ramazzini Hospital in Carpi (Modena, Italy). The patient2 Case Reports in Medicine
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presented nipple retraction of his left breast, without nipple
discharge. The physical examination revealed a 2cm ﬁrm
lump. Family history concerning parental diseases revealed
that his mother died because of breast cancer. Conventional
imaging showed an irregular mass lesion situated in the
upper outer quadrant of the left breast (Figure 1). The
patient underwent ﬁne needle aspiration at our hospital, and
the lump was diagnosed as a malignant lesion (C5 according
to the European guideline 1997). The patient had no other
associated diseases. He was not taking any medication nor
suﬀering from any known drug allergy. Modiﬁed radical
mastectomy was performed.
Histology revealed an invasive ductal carcinoma 2.8cm
wide, grade 2, with vascular and lymphatic invasion
(Figure 2).Threeaxillarynodesofthe1stlevelandtwonodes
of the 2nd level were found to be involved by metastatic
breastcarcinoma(4nodesoutof21).Surprisingly,oneofthe
second level nodes corresponded to a high-grade large B cell
lymphoma. Further immunohistochemical staining revealed
the lymphoma to be positive for CD20, CD79a, CD5 but
negative for CD3. The lymphoma was evaluated as a large B
cell non-Hodgkin’s lymphoma, according to the WHO Clas-
siﬁcation. The staging of the disease was performed by using
CT, PET, and bone scintigraphy; no other pathologic sites
were identiﬁed. The International Prognostic Index (IPI)
for the patient’s non-Hodgkin’s lymphoma was found to be
0∗ [26]. The patient was treated with local radiotherapy,
followed by 6 courses of chemotherapy (RCHOP) before
starting a treatment with tamoxifen using a dosage of 20mg
daily. Genetic investigations were performed, but no family
inheritance or gene mutations (BRCA 1 and 2) were found.
3. Discussion
Some published case reports have found two cancers in the
same patient but not simultaneously [27, 28]. An interesting
reviewconcerningnewmalignanciesamongcancersurvivors
in the US has been published in 2006 by the National
Institute of Health by using data from cancer registries over
a period of almost 30 years (1973–2000) [29]. Synchronous
malignancies (tumours diagnosed within a 6-month period)
are a very rare occurrence [30–39]. Only one small series of
female breast cancers associated to axillary non-Hodgkin’s
lymphomas has previously been reported in the literature
[25]. A family history of breast cancer was reported in
5% to 30% of cases [40, 41]. Men with a positive history
have been estimated to have an odds ratio for developing
breast cancer of 3.98 [19]. Approximately 85% of patients
experience a painless subareolar mass. Other common signs
and symptoms include nipple retraction, local pain, nipple
ulceration, and discharge [18, 21, 42]. Nipple involvement
has been reported in 40% to 50% of cases, probably in
relationtothepaucityofbreasttissueandthecentrallocation
of most tumours [13, 14, 43]. Male breast cancers have
many similarities with female malignancies, but the rarity of
the disease precludes large clinical trials, in order to deﬁne
standard treatments.
Actually, 90% of all male breast tumours are invasive
ductal carcinomas, while the remaining 10% are noninvasive
malignancies, mostly in situ ductal carcinoma [21]. Further-
m o r e ,i fc o m p a r e dt ow o m e n ,m e nh a v eah i g h e rr i s ko f
developing a second breast cancer following a ﬁrst malig-
nancy in the same patient (1 out 100 cases) [10]. Hormonal
and socioeconomic risk factors appear to be similar for both
genders, while Klinefelter syndrome (possibly associated to
BRCA2 genetic mutations), gynaecomastia, and testicular
diseases represent speciﬁc additional risk factors for male
patients [10]. Gene mutations predisposing to male breast
cancer include the above mentioned BRCA2, BRCA1,a n d
the androgen receptor gene, but an association has been
shownonlyforprostatic,gastric,andpancreaticcancers[10].
Therefore, negative results of genetic tests performed in our
patient are not surprising, because BRCA2 (and to some
extentBRCA1)mutationshavebeenproposedonlyforcorre-
lation between male breast cancer and pancreatic or prostate
cancers [10]. Also adjuvant locoregional radiotherapy was
necessary [9, 16, 20, 29, 31]. The most important prognostic
indicators are the cancer stage at diagnosis and lymph nodeCase Reports in Medicine 3
status.The5-yearsurvivalforstageIII(correspondingtoour
patient classiﬁcation) is estimated between 30 and 60%.
Most studies suggest adjuvant hormonal therapy and
chemotherapy to be started in intermediate or high risk
patients[9,16,20].Inourpatient, thehistologyof22excised
axillary nodes conﬁrmed breast cancer metastases and inci-
dental large B cell lymphoma. Treatment included adjuvant
chemotherapy with anthracyclines for the breast cancer
and ﬁrst-line therapy for large B cell lymphoma. Genetic
counseling was performed, but no germline mutations were
found. In treating our patient, standard guidelines issued for
women were followed because of lack of similar guidelines
for men.
Since men have higher response rates to additive hor-
monal therapy, this approach has been proposed as ﬁrst-line
treatment in hormone-receptor positive disease, tamoxifen
being the front-line therapy choice [44]. Despite that, no
randomised clinical trials have evaluated the use of adjuvant
tamoxifen. Several large studies retrospectively compared
men who were treated with tamoxifen in an adjuvant setting
with men who received no hormonal therapy and found
improved survival in patients in the ﬁrst group [18, 44].
However, in our case the diagnoses of breast cancer and
non-Hodgkin’s lymphoma were simultaneous prior to the
institution of any therapy. The presence of the lymphoma
was unsuspected by the clinician, but its proper assessment
allowed the patient to receive the proper therapy, based on
anthracyclines. This is the ﬁrst synchronous case reported
in literature of male breast cancer and axillary lymphoma
simultaneously conﬁrmed in the same patient. In daily
practice, we recommend that male patients with breast
swelling (gynaecomastia) should receive genetic counseling
concerning breast cancer, and undergo the same clinical
staging and treatment as women.
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